Dashboard
Manage Tickers

CERS CERUS CORP

Nasdaq cerus.com


$ 1.60 $ 0.01 (0.63 %)    

Wednesday, 15-Oct-2025 15:59:58 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 602.61 $ 4.22 (0.71 %)
DIA $ 463.04 $ 0.00 (0 %)
SPY $ 665.11 $ 2.94 (0.44 %)
TLT $ 90.76 $ -0.20 (-0.22 %)
GLD $ 387.41 $ 6.60 (1.73 %)
$ 1.59
$ 1.60
$ 1.50 x 3
$ 1.60 x 15
$ 1.54 - $ 1.61
$ 1.12 - $ 2.24
966,810
na
304.8M
$ 1.78
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-05-2025 06-30-2025 10-Q
2 05-01-2025 03-31-2025 10-Q
3 02-26-2025 01-01-1970 10-K
4 10-31-2024 09-30-2024 10-Q
5 08-01-2024 06-30-2024 10-Q
6 05-02-2024 03-31-2024 10-Q
7 03-05-2024 12-31-2023 10-K
8 11-02-2023 09-30-2023 10-Q
9 08-03-2023 06-30-2023 10-Q
10 05-04-2023 03-31-2023 10-Q
11 03-01-2023 12-31-2022 10-K
12 11-03-2022 09-30-2022 10-Q
13 08-04-2022 06-30-2022 10-Q
14 05-05-2022 03-31-2022 10-Q
15 02-22-2022 12-31-2021 10-K
16 11-02-2021 09-30-2021 10-Q
17 08-03-2021 06-30-2021 10-Q
18 05-04-2021 03-31-2021 10-Q
19 02-25-2021 12-31-2020 10-K
20 10-29-2020 09-30-2020 10-Q
21 08-05-2020 06-30-2020 10-Q
22 05-05-2020 03-31-2020 10-Q
23 02-21-2020 12-31-2019 10-K
24 10-30-2019 09-30-2019 10-Q
25 08-01-2019 06-30-2019 10-Q
26 05-07-2019 03-31-2019 10-Q
27 02-27-2019 12-31-2018 10-K
28 11-01-2018 09-30-2018 10-Q
29 08-02-2018 06-30-2018 10-Q
30 05-08-2018 03-31-2018 10-Q
31 03-08-2018 12-31-2017 10-K
32 11-03-2017 09-30-2017 10-Q
33 08-04-2017 06-30-2017 10-Q
34 05-04-2017 03-31-2017 10-Q
35 03-08-2017 12-31-2016 10-K
36 11-04-2016 09-30-2016 10-Q
37 08-05-2016 06-30-2016 10-Q
38 05-06-2016 03-31-2016 10-Q
39 03-09-2016 12-31-2015 10-K
40 11-06-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

cerus-corporation-announces-german-blood-advisory-committees-recommendation-of-intercept-for-enhanced-platelet-transfusion-safety
Cerus Corporation Announces German Blood A...
08/25/2025 13:03:51

Cerus Corporation (NASDAQ:CERS) announced today the publication of a new recommendation from the German National Blood Advisory...

cerus-raises-fy2025-sales-guidance-from-19400m-20000m-to-20000m-20300m-vs-21380m-est
Cerus Raises FY2025 Sales Guidance from $1...
08/05/2025 20:02:12

Cerus (NASDAQ:CERS) raises FY2025 sales outlook from $194.00 million-$200.00 million to $200.00 million-$203.00 million vs $213...

cerus-q2-eps-003-inline-sales-5245m-miss-5263m-estimate
Cerus Q2 EPS $(0.03), Inline, Sales $52.45...
08/05/2025 20:01:44

Cerus (NASDAQ:CERS) reported quarterly losses of $(0.03) per share which met the analyst consensus estimate. This is unchanged ...

Core News & Articles
Earnings Scheduled For August 5, 2025
08/05/2025 08:32:54

cerus-awarded-addl-72m-contract-amendment-by-us-dod-ibas-program-for-development-of-lyophilized-pathogen-reduced-cryoprecipitated-fibrinogen-complex-to-treat-bleeding-due-to-trauma
Cerus Awarded Addl $7.2M Contract Amendmen...
07/21/2025 12:35:27

Additional Funding to Support Randomized Study Evaluating Earlier Access to INTERCEPT Fibrinogen Complex in Trauma Associated H...

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
07/02/2025 21:05:48

cerus-notified-body-tv-sd-completes-review-of-clinical-module-for-ce-mark-submission-for-intercept-red-blood-cells
Cerus' Notified Body, TÜV-SÜD, Completes R...
07/02/2025 12:34:24

cerus-to-showcase-latest-intercept-blood-system-clinical-data-at-35th-regional-isbt-congress-being-held-may-31-to-june-4-2025-in-milan
Cerus To Showcase Latest INTERCEPT Blood S...
05/29/2025 12:37:04

Presentations and abstracts showcase the broad applicability and expected benefits of the INTERCEPT Blood System for platelets,...

cerus-announces-two-in-country-regulatory-approvals-for-int200
Cerus Announces Two In-Country Regulatory ...
05/28/2025 12:35:05

France and Switzerland approve INT200 for use with the INTERCEPT Blood System for Platelets and Plasma

cerus-affirms-fy2025-sales-guidance-of-19400m-20000m-vs-22192m-est
Cerus Affirms FY2025 Sales Guidance of $19...
05/01/2025 20:06:15

Cerus (NASDAQ:CERS) affirms FY2025 sales outlook from $194.00 million-$200.00 million to $194.00 million-$200.00 million vs $22...

cerus-q1-eps-004-inline-sales-4324m-miss-4962m-estimate
Cerus Q1 EPS $(0.04), Inline, Sales $43.24...
05/01/2025 20:05:56

Cerus (NASDAQ:CERS) reported quarterly losses of $(0.04) per share which met the analyst consensus estimate. This is a 20 perce...

Core News & Articles
Earnings Scheduled For May 1, 2025
05/01/2025 08:32:37

a-look-at-ceruss-upcoming-earnings-report
A Look at Cerus's Upcoming Earnings Report
04/30/2025 20:02:53

12-health-care-stocks-moving-in-wednesdays-after-market-session
12 Health Care Stocks Moving In Wednesday'...
04/02/2025 21:05:37

cantor-fitzgerald-reiterates-overweight-on-cerus-maintains-4-price-target
Cantor Fitzgerald Reiterates Overweight on...
02/21/2025 17:32:28

Cantor Fitzgerald analyst Ross Osborn reiterates Cerus (NASDAQ:CERS) with a Overweight and maintains $4 price target.

cerus-q4-2024-gaap-eps-001-inline-sales-5675m-beat-4964m-estimate
Cerus Q4 2024 GAAP EPS $(0.01), Inline, Sa...
02/20/2025 21:02:47

Cerus (NASDAQ:CERS) reported quarterly losses of $(0.01) per share which met the analyst consensus estimate. This is unchanged ...

earnings-scheduled-for-february-20-2025
Earnings Scheduled For February 20, 2025
02/20/2025 08:32:29

cerus-announces-preliminary-2024-revenues-of-1803m-up-15-from-2023-2025-revenue-projected-at-194m-200m-indicating-8-11-growth-ifc-revenue-grows-42-in-2024-2025-ifc-revenue-predicted-between-12m-15m-anticipates-led-illuminator-launch-in-europe
Cerus Announces Preliminary 2024 Revenues ...
01/13/2025 14:22:25

Preliminary Full-Year 2024 Product Revenues Total $180.3 million, 15% Over 2023 Results and Exceed Prior Product Revenue Guidan...

cerus-raises-fy2024-product-revenue-guidance-to-17700m-17900m--vs-est-18986m
Cerus Raises FY2024 Product Revenue Guidan...
10/30/2024 20:18:21

Cerus (NASDAQ:CERS) raises FY2024 sales outlook from $172.00 million-175.00 million to $177.00 million-179.00 million.

cerus-q3-2024-gaap-eps-002-beats-003-estimate-sales-46017m-miss-47335m-estimate
Cerus Q3 2024 GAAP EPS $(0.02) Beats $(0.0...
10/30/2024 20:01:29

Cerus (NASDAQ:CERS) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.03) by 33.3...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION